In 2015, reported funding for HIV prevention R&D decreased 4% from US$1.25 billion in 2014 to US$1.20 billion, continuing more than a decade of what has been essentially flat funding.

Methodology: Since 2000, the Resource Tracking for HIV Prevention R&D working group (formerly the HIV Vaccines & Microbicides Resource Tracking Working Group) has employed a comprehensive methodology to track trends in research and development (R&D) investments.
Commercial, philanthropic, and public investment in HIV prevention R&D (US$ millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>Commercial</th>
<th>Philanthropic</th>
<th>Public</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>$1.26B</td>
<td>$1.26B</td>
<td>$1.26B</td>
<td>$3.78B</td>
</tr>
<tr>
<td>2014</td>
<td>$1.20B</td>
<td>$1.20B</td>
<td>$1.20B</td>
<td>$3.60B</td>
</tr>
<tr>
<td>2015</td>
<td>$1.25B</td>
<td>$1.25B</td>
<td>$1.25B</td>
<td>$3.75B</td>
</tr>
</tbody>
</table>


- Preventive vaccines: $862M (+2%)
- Microbicides: $178M (-8%)
- PrEP: $29M (-40%)
- Treatment as prevention: $77M (-17%)
- Medical male circumcision: $6.6M (-75%)
- PMTCT: $44M (-10%)
- Female condoms: $5.9M (+63%)

Global scale of 2015 HIV prevention trial participants:
- Microbicides: 1%
- Preventive vaccine: 1%
- Male circumcision: 4%
- PrEP: 6%
- PMTCT: 22%
- Treatment as prevention: 66%

Total trial participants: 868,101

Financial support for this project was provided by AVAC and the International AIDS Vaccine Initiative (IAVI). This report is additionally made possible by the generous support of several donors, including the Bill & Melinda Gates Foundation, and the American people through the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the US Agency for International Development (USAID). The contents are the responsibility of AVAC and do not necessarily reflect the views of PEPFAR, USAID or the United States Government. AVAC does not accept funding from the pharmaceutical industry.